An observational study in Pneumonia and Bronchiolitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Assiut University · Observational
This prospective cohort study aims to evaluate neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio in children with lobar pneumonia, bronchiolitis, and bronchopneumonia compared with healthy children.
Chest infections are a leading cause of pediatric morbidity. Complete blood count-derived inflammatory ratios such as neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio are simple and inexpensive parameters that may help in the assessment of children with respiratory infections.
This observational study will include four groups of children aged 1 month to 12 years: healthy controls, lobar pneumonia, bronchiolitis, and bronchopneumonia. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and neutrophil-to-monocyte ratio will be calculated from complete blood count at admission.
2,072 studies on the registry are indexed under Pneumonia; 286 are open to participants now.
This study's planned enrollment of 120 is below the median of 200 across 699 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Children aged 1 month to 12 years with lobar pneumonia, bronchiolitis, or bronchopneumonia, and healthy children of similar age, presenting to Assiut University Children's Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Healthy children without acute respiratory illness serving as controls.
Children with clinical and radiographic findings of lobar pneumonia.
Children younger than 2 years with clinical diagnosis of bronchiolitis.
Children with clinical and radiographic findings of bronchopneumonia.
Neutrophil-to-lymphocyte ratio
Mean neutrophil-to-lymphocyte ratio calculated as absolute neutrophil count divided by absolute lymphocyte count.
Time frame: Baseline
Monocyte-to-lymphocyte ratio
Mean monocyte-to-lymphocyte ratio calculated as absolute monocyte count divided by absolute lymphocyte count.
Time frame: Baseline
Neutrophil-to-monocyte ratio
Mean neutrophil-to-monocyte ratio calculated as absolute neutrophil count divided by absolute monocyte count.
Time frame: Baseline
Number of children requiring oxygen
Number of children who require supplemental oxygen during hospital stay.
Time frame: At 14 days
Length of hospital stay
Mean length of hospital stay in days.
Time frame: At 14 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 272 non-industry observational studies under Pneumonia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's planned 12 months is below that.
Counting every sponsor, half of 281 studies reached it within 25 months; a quarter within 14 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.